PENTAS LANCEOLATA EXTRACT AND THEIR IN-VITRO COLON CANCER AGAINST HT-29 CELLINES

R. Sai Mahalakshmi^1*, P. Raja Shekar², Y. Vishwanath³, D. Rakesh Goud⁴

Corresponding Author: R. Sai Mahalakshmi*, Department of Pharmacology, Vishnu Institute of Pharmaceutical Education and Research Narsapur, Medak, Email: saimahalakshmi@myyahoo.com. 

Citation: R. Sai Mahalakshmi (2025). Pentas lanceolata extract and their in-vitro colon cancer against HT-29 cellines. Eco Science Journal.2025 2(6).

Copyrights © 2025, R. Sai Mahalakshmi. This article is licensed under the Creative Commons Attribution-NonCommercial-4.0-International-License-(CCBY-NC).

Abstract 

Cancer of the colon, commonly referred to as colorectal cancer, is a form of the disease that may affect either the colon or the rectum, both of which are components of the large intestine. It is one of the malignancies that occurs most often all around the globe. The following is essential information and data on colon cancer. Cell lines are valuable tools for investigating various aspects of colorectal cancer, including its genetics, drug responses, metastatic potential, and molecular mechanisms ^[1]. They provide a controlled environment for researchers to conduct experiments and develop a better understanding of this disease. HT-29 is a well-known and widely used human colorectal cancer cell line. The shade dried flowers of Pentas Lanceolata leaves was subjected to successive solvent extraction method by using n-Hexane in soxhlet extraction.

The in-vitro assessment of anti-cancer activity was conducted using the HT-29 cell line, which is specific to breast cancer. The PL-2 compound, obtained from the n-Hexane extract, exhibited significant anti-cancer activity. A notable decrease in cell viability was observed, with the extent of reduction being dependent on both the duration of exposure and the dosage administered was observed ^[2].

Keywords: Pentas lanceolata, Anti colon cancer activity, HT-29 Cellines, Colon cancer, Gastrointestinal tract.